Minimal residual disease assay: Definition, Uses, and Clinical Overview

Posted on February 27, 2026 | by drcancer

Minimal residual disease assay Introduction (What it is)

A Minimal residual disease assay is a test used to look for tiny amounts of cancer cells that can remain after treatment.
It is most commonly discussed in blood cancers, where it can detect disease that is not visible under a microscope.
Depending on the cancer and the assay type, it may use blood, bone marrow, or other samples.
Clinicians use it to better understand response to therapy and risk of relapse over time.

Why Minimal residual disease assay used (Purpose / benefits)

Cancer care often depends on measuring how much disease is present before, during, and after treatment. Traditional methods—such as examining cells under a microscope (morphology), imaging scans, or standard lab tests—can be very useful, but they may not detect very small amounts of remaining cancer. This is the problem Minimal residual disease assay is designed to address: identifying “residual” (leftover) disease at levels that can be below routine detection.

In many hematologic malignancies (blood cancers), response categories like complete remission may be based on the absence of detectable cancer by standard criteria. However, remission does not always mean every cancer cell is gone. A Minimal residual disease assay can add an additional layer of information by detecting low-level disease that might be associated with a higher likelihood of recurrence in some settings, or by confirming deeper responses in others.

Common goals and potential benefits include:

More sensitive response assessment: Detecting disease at very low levels can help clinicians describe response depth, especially when standard tests look normal.
Risk stratification: MRD status may help estimate relapse risk in a way that complements cancer type, stage, cytogenetics, and other prognostic factors. The clinical meaning can vary by cancer type and stage.
Treatment planning support: In selected diseases and protocols, MRD results may be one factor considered when choosing treatment intensity, duration, or next steps (for example, transplant-related decisions in certain blood cancers). Exact use varies by clinician and case.
Earlier detection of recurrence (in some contexts): Serial testing may identify returning disease before symptoms develop, although how this changes outcomes depends on the cancer and available treatments.
Clinical trials and research: MRD is often used as an endpoint or biomarker in trials evaluating new therapies, combinations, or maintenance strategies.

It is important to understand what MRD does not do. A Minimal residual disease assay does not replace diagnosis, does not “prove cure,” and is not appropriate for every cancer type or clinical situation. Results must be interpreted in the full clinical context.

Indications (When oncology clinicians use it)

Oncology and hematology clinicians may consider a Minimal residual disease assay in scenarios such as:

After initial therapy to assess depth of response in certain leukemias and lymphomas
During or after consolidation/maintenance therapy to monitor for low-level disease
Before or after hematopoietic stem cell transplant (HSCT) in selected blood cancers
When standard tests show remission but clinicians want additional risk information
When relapse is suspected but routine studies are inconclusive (case-dependent)
In clinical trials where MRD testing is part of the study protocol
For longitudinal monitoring using blood-based approaches (for example, circulating tumor DNA in some settings), where validated and clinically appropriate

Contraindications / when it’s NOT ideal

A Minimal residual disease assay is not always suitable, and there are situations where other approaches may be more appropriate or more informative:

Cancer types where MRD is not validated or not routinely used: For many solid tumors, MRD testing is still evolving, and clinical application varies by clinician and case.
Lack of a trackable marker: Some assays require a known mutation, gene rearrangement, or immunophenotype (cell-surface pattern). If none is identified, MRD testing may not be feasible.
Inadequate or poor-quality sample: For example, hemodiluted bone marrow aspirates can reduce sensitivity and lead to misleading results.
Results unlikely to change management: If the care plan would be the same regardless of MRD status, clinicians may prioritize other monitoring methods.
Timing issues: Testing too early or during transient changes in blood counts may complicate interpretation, depending on disease and treatment.
Potential confounders in blood-based molecular tests: Findings like clonal hematopoiesis (age-related blood cell mutations not caused by cancer) can complicate interpretation in some contexts.
When immediate tissue confirmation is needed: If a new mass, organ lesion, or symptomatic change strongly suggests progression, imaging and biopsy may be more direct than MRD testing alone.

How it works (Mechanism / physiology)

A Minimal residual disease assay is a diagnostic/monitoring tool, not a treatment. Its “mechanism” is the laboratory method used to detect cancer-derived cells or cancer-derived genetic material at very low levels.

At a high level, MRD detection relies on one or more of these biological features:

Abnormal cancer cell markers (phenotype): Many blood cancers show abnormal patterns of proteins on the cell surface.
Method example: multiparameter flow cytometry, which can identify rare abnormal cells among many normal cells.
Cancer-specific genetic changes (genotype): Some cancers have characteristic DNA/RNA changes—such as gene fusions, rearrangements, or mutations.
Method examples: PCR-based assays, digital PCR, or next-generation sequencing (NGS).
Circulating tumor DNA (ctDNA): In some cancers, fragments of tumor DNA can be detected in the bloodstream.
Method examples: tumor-informed assays (built from a person’s tumor profile) or tumor-naïve panels (looking for common alterations).

Relevant tissues and organ systems:

In leukemias and some lymphomas, MRD testing commonly uses bone marrow (where many blood cancers originate and persist) and sometimes peripheral blood.
In plasma cell disorders like multiple myeloma, bone marrow is often central, though blood-based approaches are being studied and used selectively.
In some solid tumors, MRD testing typically refers to blood-based ctDNA assays, reflecting tumor DNA shed into circulation.

Onset and duration/reversibility:
“Onset” and “duration” in the medication sense do not apply because MRD is a test. The closest relevant concept is timing and trend: an MRD result reflects the disease burden at the time of sampling, and serial (repeat) results can show changes over time. A negative result can later become positive, and a positive result can become negative, depending on tumor biology and treatment effects.

Minimal residual disease assay Procedure overview (How it’s applied)

A Minimal residual disease assay is usually integrated into an overall cancer-care pathway rather than performed as a standalone “procedure.” The exact workflow depends on cancer type, treatment plan, and the assay method.

A typical high-level sequence may look like this:

Evaluation/exam
Clinicians review diagnosis, prior treatments, current symptoms (if any), and the goals of testing (response assessment, monitoring, or trial requirements).
Imaging/biopsy/labs (as relevant)
– For blood cancers, routine labs and bone marrow testing may already be part of disease assessment.
– For solid tumors, imaging and pathology often anchor initial staging, and MRD testing—when used—may be added later.
Staging / risk assessment
MRD is usually not the primary staging tool, but it can add risk information in cancers where it is validated.
Treatment planning
The care team decides whether MRD testing is appropriate and which method/sample type is most suitable. Selection can depend on available markers, prior test results, and institutional capabilities.
Intervention/therapy (context for testing)
MRD testing is timed around therapy milestones (for example, after induction therapy in leukemia, after transplant, or during maintenance in certain protocols). Timing varies by clinician and case.
Response assessment (MRD testing and interpretation)
Samples are collected (blood draw and/or bone marrow aspirate), sent to a specialized laboratory, and analyzed. Results are reported as MRD detected or not detected, sometimes with additional quantitative or assay-specific details.
Follow-up/survivorship monitoring
If MRD testing is used serially, repeat testing schedules vary by cancer type, clinical protocol, and patient situation. MRD is typically interpreted alongside symptoms, physical exams, imaging (when relevant), and standard labs.

Types / variations

“Minimal residual disease” can be measured in different ways, and “Minimal residual disease assay” may refer to several assay families. Common variations include:

Flow cytometry MRD (immunophenotypic MRD)
Identifies rare abnormal cells based on patterns of surface and intracellular markers. Often used in leukemias and some lymphomas.
PCR-based MRD (molecular MRD)
Detects specific DNA/RNA sequences associated with the cancer, such as gene fusions or rearrangements. PCR approaches may be highly specific when a known target exists.
Next-generation sequencing (NGS) MRD
Uses high-throughput sequencing to identify cancer-specific sequences and detect them at low levels. In some diseases, NGS can track clonal markers over time.
Digital PCR / highly sensitive targeted assays
Can quantify specific mutations with high analytical sensitivity when a defined mutation is being followed.
ctDNA-based MRD for selected solid tumors (blood-based MRD)
Looks for tumor-derived DNA fragments in plasma. Some tests are tumor-informed (customized using tumor tissue), while others use predefined gene panels. Clinical use and interpretation vary by cancer type and stage.
Disease- and age-specific applications (adult vs pediatric)
Pediatric leukemias often incorporate MRD into risk stratification within protocol-driven care. Adult use also exists but may differ by disease subtype, treatment approach, and guideline context.
Setting differences (inpatient vs outpatient)
Sampling may occur during hospital-based treatment (for intensive chemotherapy or transplant) or in outpatient follow-up. The laboratory analysis is typically centralized or performed in specialized reference labs.

Pros and cons

Pros:

Detects very low levels of disease in some cancers when routine tests appear normal
Can provide additional prognostic and risk information beyond standard remission criteria
Useful for monitoring trends over time when performed serially in appropriate settings
May help standardize response assessment in clinical trials and protocol-based care
Can sometimes reduce uncertainty when clinical findings are borderline or ambiguous
Supports more individualized discussions about response depth (context-dependent)

Cons:

Not equally validated or informative across all cancer types; usefulness varies by cancer type and stage
False negatives can occur (for example, due to sampling issues or disease located outside the sampled compartment)
False positives or confusing results can occur, especially with blood-based molecular testing in the presence of confounders
May require invasive sampling (bone marrow aspiration) depending on the disease
Results can be complex to interpret and must be integrated with clinical context
Testing availability, turnaround time, and insurance coverage can vary by region and institution
A change in MRD status does not automatically dictate a single “correct” treatment choice

Aftercare & longevity

Because a Minimal residual disease assay is a test, “aftercare” mainly involves what happens after results are returned and how monitoring is planned over time.

Key factors that can influence how MRD results are used and how durable a response may be include:

Cancer type and stage: MRD has well-established roles in some hematologic malignancies, while in many solid tumors the clinical role is still emerging. Prognostic meaning varies by cancer type and stage.
Tumor biology: Cytogenetics, molecular risk features, and disease subtype can affect relapse patterns and the significance of MRD findings.
Treatment intensity and sequence: Induction, consolidation, transplant, and maintenance strategies differ across cancers and can influence MRD dynamics.
Depth and consistency of response: A single MRD result is a snapshot; trends over time can be informative when a validated testing approach is used.
Sampling and assay choice: Bone marrow vs blood, and flow vs molecular methods, can lead to different detection performance depending on where disease tends to reside.
Follow-up infrastructure: Access to regular oncology follow-up, laboratory services, and survivorship care can affect how consistently monitoring is performed.
Comorbidities and supportive care: Other health conditions and treatment tolerability can shape what monitoring or additional therapy is feasible, which indirectly affects outcomes.

In survivorship contexts, clinicians often combine MRD information (when used) with symptom review, physical exams, routine labs, and imaging when appropriate. The overall goal is to monitor health status and detect clinically meaningful changes early enough to address them within the broader care plan.

Alternatives / comparisons

Minimal residual disease testing is one tool among many. Alternatives or complementary approaches depend on the cancer type and the clinical question (response assessment, surveillance, or suspected relapse).

Common comparisons include:

Standard pathology/morphology vs Minimal residual disease assay
Microscopy can identify obvious disease and remains essential for diagnosis and many response assessments. MRD methods are often more sensitive in certain blood cancers, but they are more specialized and may not capture all disease patterns.
Imaging (CT, PET/CT, MRI) vs Minimal residual disease assay
Imaging is central for many solid tumors and lymphomas to evaluate tumor size and distribution. MRD (especially ctDNA-based approaches) may provide molecular information that imaging cannot, but imaging is often better for locating disease and assessing complications.
Tumor markers and routine labs vs Minimal residual disease assay
Some cancers have blood markers (for example, protein markers in plasma cell disorders). These can be useful and widely available, but they may be less specific or less sensitive in certain settings than MRD methods, depending on the disease.
Bone marrow biopsy/aspirate assessments without MRD vs MRD-enabled evaluations
Standard bone marrow evaluation can show remission or persistent disease, while MRD methods can add sensitivity. However, bone marrow sampling is invasive and may not reflect disease in other sites.
Observation/active surveillance vs MRD-informed monitoring
In cancers where observation is an accepted strategy, clinicians may rely on symptoms, exams, labs, and imaging. MRD testing may add information in some scenarios, but whether it changes management or outcomes varies by clinician and case.
Standard care vs clinical trials
In trials, MRD may be required and used to compare therapies or define endpoints. In standard practice, MRD use may be more selective and shaped by guidelines, local resources, and individual risk factors.

Minimal residual disease assay Common questions (FAQ)

Q: Is a Minimal residual disease assay the same as being “cancer-free”?
No. MRD testing looks for disease below standard detection, but a negative result does not guarantee every cancer cell is gone. It means disease was not detected by that specific assay in that specific sample at that time.

Q: Does the test require a bone marrow biopsy, and is it painful?
Some MRD testing is done on peripheral blood, but many blood cancers use bone marrow aspirate samples. Bone marrow procedures can be uncomfortable; pain control approaches vary by clinic and patient needs. The MRD laboratory test itself is performed on the collected sample.

Q: Is anesthesia used for MRD testing?
For blood draws, anesthesia is not used. For bone marrow sampling, local numbing medicine is common, and some centers use additional medications for comfort depending on the situation. Practices vary by institution and case.

Q: How long does it take to get results?
Turnaround time depends on the assay type, the laboratory, and whether specialized processing is required. Some methods can return results relatively quickly, while others may take longer due to complex sequencing and analysis. Your care team typically interprets results alongside other tests.

Q: What does “MRD-positive” or “MRD-negative” mean?
MRD-positive generally means residual cancer-related cells or genetic material were detected by the assay. MRD-negative generally means the assay did not detect residual disease in that sample. The clinical implications vary by cancer type and stage, and by the method used.

Q: Can MRD testing replace scans or other follow-up tests?
Usually not. MRD testing is typically complementary, not a complete replacement for imaging, exams, and standard labs. Many cancers require imaging or other assessments to evaluate disease location, organ involvement, and treatment effects.

Q: Are there risks or side effects from MRD testing?
The main risks relate to sample collection rather than the assay. Blood draws can cause bruising or lightheadedness, and bone marrow sampling can cause soreness and rare complications such as bleeding or infection. The laboratory analysis itself does not expose the body to radiation or drugs.

Q: How often is a Minimal residual disease assay done during follow-up?
Testing schedules vary by disease, treatment protocol, and clinician preference. Some care pathways use MRD at specific milestones (after induction, after transplant, or during maintenance), while others use it only when clinically indicated. There is no single schedule that fits all cancers.

Q: How much does MRD testing cost?
Costs depend on the assay technology, the laboratory, how often testing is performed, and insurance coverage or health system policies. Out-of-pocket expenses can vary widely. Billing and coverage questions are best addressed through the treating center’s financial services team.

Q: Does MRD testing affect fertility or pregnancy?
The test itself does not affect fertility because it is an analysis of blood or marrow samples. However, MRD results may be used in discussions about cancer treatment intensity or duration in some settings, and cancer treatments can affect fertility. Fertility and pregnancy considerations should be addressed with the oncology team as part of overall care planning.